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Background: In somatic cancer genomes, delineating genuine driver mutations against a background of multiple
passenger events is a challenging task. The difficulty of determining function from sequence data and the low
frequency of mutations are increasingly hindering the search for novel, less common cancer drivers. The
accumulation of extensive amounts of data on somatic point and copy number alterations necessitates the
development of systematic methods for driver mutation analysis.
Results: We introduce a framework for detecting driver mutations via functional network analysis, which is applied to
individual genomes and does not require pooling multiple samples. It probabilistically evaluates 1) functional network
links between different mutations in the same genome and 2) links between individual mutations and known cancer
pathways. In addition, it can employ correlations of mutation patterns in pairs of genes. The method was used to
analyze genomic alterations in two TCGA datasets, one for glioblastoma multiforme and another for ovarian carcinoma,
which were generated using different approaches to mutation profiling. The proportions of drivers among the
reported de novo point mutations in these cancers were estimated to be 57.8% and 16.8%, respectively. The both sets
also included extended chromosomal regions with synchronous duplications or losses of multiple genes. We identified
putative copy number driver events within many such segments. Finally, we summarized seemingly disparate
mutations and discovered a functional network of collagen modifications in the glioblastoma. In order to select the
most efficient network for use with this method, we used a novel, ROC curve-based procedure for benchmarking
different network versions by their ability to recover pathway membership.
Conclusions: The results of our network-based procedure were in good agreement with published gold standard sets
of cancer genes and were shown to complement and expand frequency-based driver analyses. On the other hand,
three sequence-based methods applied to the same data yielded poor agreement with each other and with our
results. We review the difference in driver proportions discovered by different sequencing approaches and discuss
the functional roles of novel driver mutations. The software used in this work and the global network of
functional couplings are publicly available at http://research.scilifelab.se/andrej_alexeyenko/downloads.html.
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Cancer diseases result from stable perturbations in the
network of functional interactions between genes and
proteins. Which particular molecular mechanism was
involved in any given case is less important than where
in the network the alteration occurred. This is why
attempts to understand cancer from the perspective of
single genes or specific molecular mechanisms fail so
often.
Recent large-scale investigations have demonstrated that
cancer genomes are typically altered at multiple points in a
single tumor [1-5]. Cancers with similar phenotypes may
have hundreds of genomic alterations each, but these lists
have low overlap with each other. There are two main
reasons for this: 1) multiple different perturbations can
generate identical cell states via alternative network routes
[6], and 2) given the failure of chromosome repair mecha-
nisms, spurious non-deleterious mutations start to occur
at random. Many mutations discovered in cancer cells are
thus neutral passengers that merely accompany function-
ally important drivers that have been subject to selective
pressure. These mixtures of passenger and driver muta-
tions together comprise the mutated gene sets (MGS) of
the tumors in question. It is important to delineate the
driving components of MGS both to facilitate basic re-
search and to enable the development of individualized
cancer therapies. Such information is important for several
reasons. For example, some drivers should be targeted
simultaneously during chemotherapy while others need to
be targeted in a staggered fashion [7-10]. Similarly, it will
be important to distinguish between different molecular
subtypes of a particular cancer in order to identify the most
appropriate treatment [11].
However, because each individual tumor will exhibit a
unique combination of perturbations and random non-
deleterious mutations, it is not trivial to identify the
drivers within a given MGS. Estimates of the true driver
fraction have ranged from a few percent [12] to around a
half of all point mutations. The analysis of large,
chromosome-scale copy number changes is even more
challenging than that of point mutations. Specific chromo-
somal regions exhibit recurrent aberrations in over 50% of
all cases of certain cancer types, such as ovarian carcin-
oma [13]. While these may include tens, hundreds, or
even thousands of genes, it is intuitively clear that only a
few of them are relevant to the disease. Many studies have
been based on the hypothesis that mutations that occur
frequently in cancers are most likely to contribute to can-
cer progression [1]. Sequence-based analyses have been
used to distinguish between functional hot spots of indi-
vidual genes such as TP53, which were identified as
drivers, and non-functional mutations in the same gene
[14]. Other authors have examined mutation patterns at
the sequence level such as the ratio of synonymous tonon-synonymous mutations [2] or the rates of break-of-
translation mutations [15] while others have examined the
potential functional consequences of specific mutation
patterns [16] and the associated changes at the amino acid
level [17]. Leary and co-authors [18] analyzed rates of se-
quence mutation and copy number changes simultan-
eously. To facilitate the discovery and classification of
novel oncogenes and tumor suppressors, Vogelstein and
co-authors [19] introduced the “20/20 rule”: a driver gene
can be classified as an oncogene if at least 20% of its
recorded mutations are missense mutations that occur at
recurrent positions, and as a tumor suppressor gene if at
least 20% of its recorded mutations are inactivating.
Many attempts to disentangle gain and loss patterns in
large chromosomal regions have incorporated analyses of
expression [20]. The GISTIC method identified driver gene
copy number alterations (CNA) [21] by analyzing the stat-
istical frequencies of various features, thus necessitating
the use of large samples. Ciriello et al. [22] demonstrated
that a given gene may exhibit different forms of alteration
(e.g. copy number changes, point mutations, or changes in
methylation) in different tumors. However, their method
also can only identify cancer drivers in frequently mutated
genes and chromosome-level patterns. As an example
estimation of sample size required for such studies, the
International Cancer Genome Consortium [23] determined
that 500 samples per tumor type would be needed to
detect a novel cancer gene that is mutated in at least 3% of
patients. Vogelstein et al. [19] reviewed the challenges
associated with the complex mutation landscapes of tumor
genomes. Based on an analysis of 294,881 reported muta-
tions from 3284 tumors that yielded only 125 discovered
or confirmed drivers, they concluded that “at best, methods
based on mutation frequency can only prioritize genes for
further analysis but cannot unambiguously identify driver
genes that are mutated at relatively low frequencies”. In
other words, the vast majority of cancer genes have rates
of mutation that are too low to enable their detection by
frequency-based analyses. It will therefore be necessary to
consider their functional and genomic contexts in order to
determine their roles in specific cancers.
Considering the functional relationships between genes
introduces a new dimension in the search and may radic-
ally improve the detection of driver mutations. One way
to analyze these relationships is to establish and use a glo-
bal network of functional couplings. Broadly defined, such
a network consists of nodes (which represent genes,
proteins, and potentially other molecules) and edges, i.e.
functional links that connect them. An account of early ef-
forts in the network analysis of disease genes and specific-
ally those associated with cancer has been written by
Ideker and Sharan [24]. The network edges are expected
to link genes that were mutated in the same genome more
densely than would be expected by chance alone. We have
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tome [25] by examining mutations from glioblastoma
multiforme (GBM) brain tumors obtained via The Cancer
Genome Atlas project [26].
Torkamani and Schork [27] analyzed the functional
contexts of mutated genes in co-expression modules.
Cerami et al. [28] employed a network of protein-
protein interactions to systematically evaluate the rela-
tionships between the most common mutations in
GBM. They pooled the GBM point mutations in a
larger sub-network (>300 genes) of potential drivers
and investigated its modular structure. Subsequently,
Ciriello et al. [29] utilized negative correlations (s.c.
mutual exclusivity) between the most frequent muta-
tions to identify multiple smaller modules, called cli-
ques, in the protein interaction network. However,
none of these methods were capable of detecting the
involvement of specific mutations in each individual
tumor. Gu et al. [30] also demonstrated that driver
genes produced modular structures, and that different
modules depended on each other in the network of
physical protein-protein interactions. Babaei et al. [31]
developed a multi-scale graph diffusion algorithm
which confirmed that somatic mutations tend to
gather around particular spots in the network. The di-
mensionality of such spots can range from single
genes (frequent mutators) to larger pathway-like
structures that are sparsely populated with rare muta-
tions. An appealing feature of the three latter methods
is that individual mutation effects are generalized to
larger network modules which recur in different can-
cers. This reflects the observation that multiple driver
mutations co-operate within a genome. In order to
analyze large-scale chromosomal alterations, Akavia
et al. [20] introduced an approach whereby copy num-
ber gains and losses were evaluated in terms of their
impact on the expression of other genes and the asso-
ciated modules, although this method also uses the
frequency of occurrence as an input variable. In
addition, functional relationships between genes were
identified based on transcriptome responses within the
analyzed dataset rather than being obtained from a large
and previously-established interactome. Another advanced
method for finding driver copy number alterations (CNA)
[31] uses networks to identify the most important driver
pathways rather than individual driver CNA events in par-
ticular genomes. This approach was largely based on the as-
sumption that CNA changes the expression of either the
directly affected gene or its network neighbors. On the
other hand, many researchers (including Akavia and co-
authors [20]) argued that, due to selective pressure, the ex-
pression of CNA drivers tends to be less correlated with
their own copy number than the expression of certain pas-
senger CNAs.The common feature of all these frequency- and
network-based methods is that they are global, i.e. require
summarizing observations across multiple samples. How-
ever, it is intuitively clear that local contexts are important,
and that the role of a certain mutation might depend
on other alterations in the genome. As such, even rare
mutations may be essential in driving a specific in-
stance of cancer. However, it would be impossible to
identify or study such rare mutations in a global ana-
lysis because of the low statistical power of the latter in
such situations.
Therefore, we have developed a new, local approach
to network analysis in order to distinguish between
driver and passenger genes. We designed and have
previously used an algorithm of the network enrich-
ment analysis (NEA, [32]) to identify and probabilistic-
ally evaluate functional relationships between various
experimental and known gene sets including GO terms
[33], pathways [34,35], differentially expressed tran-
script lists [32], and lists of candidate disease genes
[36-38]. The key property of NEA is that it can be used
to evaluate the statistical significance of observations
by calculating the likelihood that they would occur by
chance alone, i.e. in a random network. In our view, an
optimal network-based algorithm would test individual
mutation events against functional gene sets (FGS).
Thus, NEA can identify driver mutations by consider-
ing the relationships between individual events in each
somatic genome and 1) other mutations in the same
genome and 2) genes that constitute known cancer
pathways.
The article is organized as follows. We present:
1) The principle and main components of a new
method for the network analysis of cancer genes and
explain the choice of required components and
parameters.
2) The results of an analysis of the two cancer sets that
were published by the Cancer Genome Atlas
consortium: glioblastoma (GBM) and ovarian
carcinoma (OV) [13,26]. We report all of the
findings obtained and suggest potential biological
roles for the most interesting novel drivers.
3) Results that validate our network-based method and
comparisons of its performance to that of existing
methods.
Finally, we discuss the strengths, weaknesses, and applica-
tion domains of different approaches for identifying driver
genes. The optimal global network and the software used in
our analysis are made freely available. Our perl program
NEA.pl can be used to perform multi-pronged and multi-
lateral statistical evaluations of biological hypotheses in the
network context.
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The method: parallel procedures to test driver roles
The application of NEA [32] to single mutations can be
briefly described as follows: it evaluates significance of
the functional relation between the mutated gene and a
pre-defined set of genes which are known or supposed
to functionally relate to each other. This is done by
counting network edges (links) between the given gene
and any other genes of the set in the actual global
network. Next, the links are counted in the same way in
a random network, which provides the count expected
by chance. If it is significantly lower than the actual
count (given the observed level of variance in a suffi-
ciently big series of random networks), then NEA claims
that there is functional relation between the mutation
and the gene set. The details are explained in the section
“Connectivity tests” (see Methods).
The multiplicity of observed somatic mutations in most
cancer genomes indicates that the emergence of cancer
might require perturbations at multiple network points.
This conjecture was confirmed in our previous work [25]:
many individual, tumor-specific sets of somatic mutations
in GBM exhibited coherence in the global network
context when analyzed as whole groups (or mutated gene
sets, MGS). A representative case is shown in Figure 1A.
This coherence was demonstrated by the presence of a
greater number of connections between simultaneously
mutated genes than the number expected by chance alone
(analysis details for the GBM and OV sets are given under
the heading “Coherence of genome-specific sets of point
mutations” in the Methods section). This allows us to
suggest that MGSs could be used as functional gene sets
needed for the NEA tests in the current work. Each par-
ticular mutation in the MGSs may be either a passenger,
and then no enrichment to the rest of MGS should be de-
tected, or a driver, and then we should obtain a significant
network enrichment score (if the global network con-
tained relevant edges). In addition to using MGSs, we can
test each mutation against known cancer pathways. In this
case, we expect that the mutation interacts with pathway
genes, while the latter are not necessarily mutated in this
genome. Thus, we applied three modes of NEA in parallel,
independently of each other (illustrated in panels B, C,
and D of Figure 1), and combined their results at the last
step (Figure 1E). In these modes the individual genomic
alterations (i.e. point mutations or copy number changes
that could influence protein-coding genes) were evaluated
against:1) the sets of all point mutations in the same genomes
(referred to as 1point-vs-MGS or 1CNA-vs-MGS
evaluations, respectively), or
2) the known cancer pathways (1-vs-CPW);It should be noted that we did not analyze copy num-
ber changes with respect to one-another because they
were very abundant and positionally coupled, so that
such an analysis would have yielded high false positive
rates. Instead, we evaluated each of the copy number
altered genes for their statistical significance of co-
occurrence (CO) with any point mutations across
tumors of the same cancer type (Figure 1E; details of this
analysis are provided under the heading “Validation by
co-occurrence of mutations” in the Results section).
Thus, after completing all these tests, each mutation
event was assigned two or three (if the CO analysis was
included) separate p-values, which were then combined
using Fisher’s formula and adjusted for multiple testing.
According to the Fisher’s definition, a significantly low
combined p-value would suggest that the candidate
driver was involved in at least one (and possibly two or
all three) of the roles. The candidate drivers were then
ranked according to their combined p-values.
Selection of parameters
Network enrichment statistics
Our software was capable of calculating network statistics
(see “Connectivity tests” in Methods) by counting both
direct links (i.e. existing network edges) and indirect links
in which two genes shared a neighbor (i.e. both nodes of
interest had edges connecting them to the same third
node). A preliminary study indicated that the inclusion of
indirect links improved the method’s performance when
dealing with sparse networks. While the latter are dis-
cussed in the following section, the method’s overall sensi-
tivity and specificity when analyzing sparse networks were
consistently worse than those achieved for more dense net-
works even if only direct links were considered in the
dense cases (data not shown). We therefore primarily
employed analyses using direct links.
Choosing the optimal network
So far, many alternative versions of the global network of
functional coupling in human (otherwise called gene
regulatory network, interactome etc.) have been made
public. Hence generation or compilation of a novel net-
work version was beyond our focus in this work. In order
to optimize the discovery of cancer drivers, we wanted to
identify by benchmarking the most efficient global net-
work in our collection of public and custom networks,
also considering possible merges thereof. The previously
published network analyses have often utilized physical
protein interactions obtained from the literature and high-
throughput experiments [28,29,38]. However, given the
multiplicity of interaction mechanisms in the underlying
biological network, the systematic integration of diverse
high-throughput data types should provide a more in-
formative resource [39-42]. Our FunCoup framework [25]
Figure 1 Schematic representation of the network enrichment analysis applied to detection of driver mutations. A, total quantification of
inter-relations between somatic point mutations (PM) in one genome. B, test of a single point mutation for being related to all other PMs (1point-vs-MGS).
C, test of a copy number alteration (CNA) against all PMs in the same genome (1CNA-vs-MGS). D, test of either a CNA or PM against a known cancer
pathway (CP), irrespective of genome (1-vs-CPW). E, overview of the algorithm. The analyses at B, C, and D were summarized into a single combined
p-value for each gene copy number change (yellow) and point mutation (red).
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high confidence and coverage, which was achieved by
incorporating eight different types of data from a range of
model eukaryotes as well as from the human itself. How-
ever, the relevance of such broad data collections in the
cancer domain was questioned. A priori, it was not clear
whether it would be best to focus on a network with the
maximum achievable size and coverage (with the risk of
lower specificity as a possible trade-off), a high-confidence
curated network, or a cancer-specific network based on
only the most immediately relevant data.
To clarify this issue, a benchmarking study was con-
ducted (for details, see the Methods section). The best
performance was achieved with a network obtained by
merging the FunCoup data with links available from a
number of curated databases (Figure 2). All of theanalyses presented herein were based on this combined
network, which was named merged6_and_wir1_HC2 and
is available for downloading at http://research.scilifelab.se/
andrej_alexeyenko/downloads.html. For the sake of sim-
plicity, the types, origins, and strengths of the net-
work edges are omitted in figures highlighting relevant
examples.
Discovery of driver mutations
Point mutations
We tested all of the point mutations reported in the
MAF files for the GBM and OV sample collections, for
which 1020 and 14842 somatic point mutation events in
gene coding regions were identified, respectively. Using
the procedure described above (the first section of
Results), we performed 1point-to-MGS and 1-vs-CPW
Figure 2 ROC curves allow evaluating differential performance of global network versions in predicting members of cancer-related
gene sets. Crosses: points where FDR = 0.1. OR (“odds ratios”) quantify sensitivity/specificity trade-offs as ratios of Y/X coordinates at the
cross points.
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minimal adjusted combined p-value confidence threshold
of 0.01, we classified 591 and 2506 mutations in the GBM
and OV sets as drivers (Sheet 1 in Additional file 1), where
these numbers corresponded to 259 and 1258 distinct
genes, respectively. The two sets were originally produced
using different approaches: the OV set was generated in a
whole-exome effort whereas the GBM set was generated
by analyzing a pre-defined set of around 600 genes
selected on the basis of previous cancer studies. The MGS
for GBM were consequently smaller (7 mutations per
GBM sample compared to more than 50 per OV
sample) and were found to contain a greater propor-
tion of drivers in our analysis: 57.8% of the GBM mu-
tations were identified as drivers compared to only
16.8% of those in the OV set. The sensitivity of the
analysis of the GBM set thus appeared to represent a
trade-off between lower MGS sizes (which would be a
disadvantage for NEA) and a greater proportion of
real drivers due to the target gene pre-selection
(which increased the statistical power of the analysis).
The 1-vs-CPW procedure was, on average, more sen-
sitive than the 1point-vs-MGS one: around 50% of all
detected drivers could have been successfully qualified
using 1-vs-CPW alone. However, the 1point-vs-MGSanalysis complemented the 1-vs-CPW results by increas-
ing the overall confidence and sensitivity.
How often were mutations in the same gene classified
differently in different samples (i.e. as drivers in one case
and passengers in another)? There were 25 such genes
out of 196 that were mutated twice or more in the GBM
set, and 94 genes out of 2755 multiply-mutated genes in
the OV set. Most of these mutations occurred in
genomes with small MGS size, which were not amenable
to 1point-vs-MGS analysis. However, many of them had
also been linked to known cancer pathways in previous
studies and were therefore assigned low p-values in the
1-vs-CPW analysis.
Figure 3 exemplifies the network analysis with 34
point mutations from the GBM sample TCGA-02-0014.
More than half of the genes were assigned low combined
p-values because they had significant connections to
known cancer pathways (red circles), to other genes with
point mutations in the same genome (black crosses), or
both (red crosses). Nine genes were qualified as passengers
in this set (black circles). The network view reiterates the
importance of statistical estimation: there were several
cases in which a node had many links but was not
significant. For example, while MAPK10 had three edges
connecting it to other mutated genes, it was not qualified
Figure 3 Network enrichment analysis of point mutations in genome TCGA-02-0014. The likelihood that one of the 34 mutated genes in
the genome (indicated by red and black nodes) was determined either based on their linkage to the set of other 33 point mutations (black
crosses), or in the context of known cancer pathways (red circles), or by both criteria (red crosses). Mutations that did not reveal any functional
involvement are indicated by black circles. Linkage to cancer pathways is exemplified by the relationship between TGFBR2 and the genes of the
KEGG05214 glioma pathway (green circles). Other relationships of this type are not shown.
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node itself had a high degree (468) as did the three other
mutated kinases (MAPK9, TNK2, and PRKDC, which had
403, 360, and 1212 network edges, respectively). The pres-
ence of three edges was therefore considered to be spuri-
ous in this case. However, it should be noted that
MAPK10 was identified as a driver in the CPW analysis.
Resolving copy number altered regions: gene copy gains
and losses versus somatic point mutations
This section describes the justification for the CNA
analysis, the procedure for performing it, and the results
obtained using it.
Both the GBM and OV genomes often exhibited substan-
tial chromosomal re-arrangements that involved thousands
of potential driver genes. Therefore, using CNAs in the
same way as point mutations would have resulted in a low
power to detect functional involvement. Another complica-
tion was that even though many chromosomal segments
appeared to be recurrently affected across either GBM or
OV, their borders were ambiguous (i.e. varied from genome
to genome). This again justified the use of the gene-wise
approach.
First, we checked whether copy number changes had
a tendency to be related to the point MGS in the same
cancer genome. CNA genes were indeed enriched infunctional associations with sets of point mutations.
For example, at a threshold of 35.3% below the normal
copy number value, significant enrichment was demon-
strated for both the GBM and OV sets (the p-values of
the Fisher’s exact test were below 10−13 in both cases).
As with the pairwise co-occurrence of point muta-
tions described above (in the section on “Validation by
co-occurrence of mutations”), we observed many cases
in which CNAs co-occurred with point mutations in
other genes. However due to the large sizes of the studied
chromosomal fragments, chromosomal neighbors appeared
in large clusters with identical or very similar patterns of as-
sociation with certain point mutations. Such extended
chromosomal fragments have long been linked to cancer in
epidemiological studies, but identifying specific drivers
among their many genes remained challenging.
In order to identify CNA drivers, we applied our
network analysis to every CNA gene within each of
the chromosome fragments. For each such gene, we
calculated
1) their co-occurrence with each point mutation in
the cohort; only genes having a p-value of <0.01
for co-occurrence with at least one point mutation
according to Fisher’s exact test were regarded as
potential drivers,
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calculated with regard to MGS for all genomes in
which the copy number of the corresponding gene
was changed, and
3) 1-vs-CPW, i.e. the NEA z-scores for their relationships
to known cancer pathways.
The p-values for these tests were combined hierarchic-
ally as described in the Methods and used to prioritize po-
tential CNA drivers (Sheet 2 in Additional file 1). This
analysis was much more sensitive for the GBM data set
than for the OV set, yielding 365 and 90 prioritized driver
CNAs with combined p-values of p < 10−6 and 232 and 61
genes with combined p-values of p < 10−12, respectively.
Aside from possible biological differences between the sets,
the main reason for this is probably the lower sensitivity of
NEA against point MGS in the OV set (which contained a
much greater proportion of passengers than the GBM set,
as discussed above). We note that the whole analysis (i.e.
that based on the application of all three conditions to-
gether) was probably too conservative and may have yielded
many false negatives.Figure 4 Driver analysis over extended chromosomal regions. All the c
chromosome 7 in the ovarian cancer. The grey areas mask the chromosomal
shown. Multi-colored bars in the lower plot indicate the copy numbers in ind
line). Grey lines indicate the 10th, 25th, 50th, 75th, and 90th percentiles of copy
genes based on the–log10 of their combined p-values: genes with higher pos
the 1-vs-CPW analysis are highlighted in red, those highly significant in the 1C
indicate genes highly significant in both analyses. Gene symbols in brac
CNAs. A complete version of this figure can be found in the Additional
pdf and OV.CNA_drivers_along_chromosomes.pdf.We visualized the results of all three tests and their
combined results using chromosomal maps (Figure 4 and
Additional file 2: GBM.CNA_drivers_along_chromosomes.
pdf and Additional file 3: OV.CNA_drivers_along_chromo-
somes.pdf). Figure 4 shows the results of the analysis for
chromosome 7 in the OV set. While the copy numbers var-
ied along the chromosome’s length, there were only a few
regions in which these variations significantly co-occurred
with point mutations in such genes as TP53, BRCA2, or
TTN (see names in brackets) and thus satisfied the first
condition. Next, only some of these genes were further
functionally linked to either a given MGS (indicated with
an asterisk) or to a particular cancer pathway (indicated by
red coloration). A few genes satisfied all three criteria:
EGFR, PIK3CG, HBP1, OPN1SW, MET, and CALD1. The
left chromosomal arm probably exhibited a tendency to-
ward duplication primarily because this increased the copy
number of EGFR. Variations in the other chromosomes
may have affected a number of different drivers. Interest-
ingly, in the GBM cohort, EGFR CNAs co-occurred with
point mutations in the same gene (mostly of the missense
type): out of 24 genomes with point mutations in EGFR, 22omponents of NEA were run over copy-number altered regions of
regions omitted from this plot, so that only four selected regions are
ividual OV genomes relative to the reference diploid genome (dotted red
number in the OV cohort. The upper plot shows the prioritization of
itions are more highly prioritized. Genes found to be highly significant in
NA-vs-MGS analysis are marked with a black asterisk, and red asterisks
kets indicate point mutations that co-occurred with the driver
file 2 and Additional file 3: GBM.CNA_drivers_along_chromosomes.
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other GBM samples that contained EGFR duplications but
no EGFR point mutations.
Analyses spanning multiple samples revealed interesting
functional relationships. For example, copy losses in a
region of chromosome 5 strongly suggested that both
GRIA1 and PTTG1 were potential drivers. Both of these
CNAs were originally prioritized because of their co-
occurrence with point mutations in TP53, and subse-
quently exhibited tight functional links to specific MGS.
In a sub-network of two MGS involving GRIA1, PTTG1,
TP53, and other MGS members from two representative
OV genomes, only PTTG1 was directly linked with TP53
(Figure 5). The functional association between GRIA1 and
TP53 was thus revealed via their connections to other
mutations.
The collagen network
In addition to the oncogenes and tumor suppressors that
perform controlling functions in cancer, we identified a
group of structural proteins with apparent functional roles
in GBM and OV. Mammoto et al. [43] summarized the
molecular mechanisms of brain cell compaction and
angiogenesis in glioblastoma multiforme. In experimental
studies on glioblastoma cell lines, these authors demon-
strated that changes in the expression of genes encoding
proteins such as lysyl oxidase (LOX), collagens of groups
2, 4, and 6, and metalloproteinases 2 and 9 were associ-
ated with changes in the physical microenvironment of
the extracellular matrix in neoplastic brain tissues. Colla-
gens were affected by point mutations in 16 of the 148
GBM genomes and 102 of the 326 OV genomes. All ofFigure 5 Close functional relationships between genes with point mu
The relations were first prioritized for their significant co-occurrence with poin
with other point mutations. Red nodes indicate genes with point mutations d
a pair of genes that both exhibited copy number losses in the same genomethese cases from the GBM set and around 50% of those
from the OV set scored highly in our driver analysis.
Furthermore, many collagens exhibited either copy
number alterations or had point mutations that co-
occurred with CNA in other genes. However, neither
LOX itself (which enables neoplasia by cross-linking
collagen chains) nor the three human LOX homologs
exhibited any genomic alterations. Figure 6 shows a
sub-network that combines all of the relevant proteins
that exhibited mutagenesis in the GBM set. Each of the
presented genes is connected to multiple structural and
regulatory interactors of the extracellular matrix, tumor-
related angiogenesis, and tissue formation: matrix metallo-
proteinase MMP9, fibronectin FN1, fibulin-1 FBLN1,
laminin beta LAMB2, extracellular sulfatase SULF1,
oncostatin M OSMR, bifunctional 3’-phosphoadenosine
5’-phosphosulfate synthetase-2 PAPSS2, galectin-3-binding
protein LGALS3BP, “LIM and cysteine-rich domains 1”
LMCD1, PDGF receptor PDGFRB, prostacyclin synthase
PTGIS, probable carboxypeptidase X1 CPXM1, syndecan
SDC4, WNT1-inducible proteins WISP1and WISP2, and
cysteine-rich angiogenic inducer 61 CYR61.
Each of the nodes shown in Figure 6 (aside from the
LOX genes) represents a gene with either a point mutation
(red) or a CNA (yellow) in GBM. Their roles as drivers
were confirmed by both NEA and their co-occurrence with
other mutations (Additional file 1). On a larger scale
(data not shown), this sub-network was linked to EGFR
through FN1, LMCD1, PDGFRB, tenascin TNC, and
integrin beta-3 ITGB3, as well as to protein kinases
PIK3CA and PIK3C2A through CPXM1, SDC4, and
WISP2.tations and copy number changes in the same somatic genome.
t mutations in TP53, and then for enrichment in network connections
etected in the OV tumor sample TCGA-13-0906-10; Yellow nodes indicate
, both of which were highly ranked as drivers in this genomic context.
Figure 6 Collagen-associated network affected by somatic mutagenesis in GBM, as identified by the network analysis. The sub-network
was retrieved from http://funcoup2.sbc.su.se by searching for direct links that connect genes with point mutations (red), copy number alterations (yellow),
and LOX genes (grey). Each of the red and yellow nodes represents a gene with a driver role established via 1) network enrichment analysis against either
known cancer pathways or sets of genes with point mutations in the same tumor, and 2) significant association (co-occurrence) with collagen mutations
(or being collagens themselves). The network edges shown in the figure are independent of the latter analysis because the whole network was compiled
using the FunCoup tool based on multiple sources of high-throughput, annotation, and literature data.
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though in these cases somatic mutagenesis affected
collagens of classes 11, 12, 14, and 16, as well as genes
encoding HSPG2 (basement membrane-specific hepa-
ran sulfate proteoglycan core protein) and MXRA5
(matrix-remodelling-associated protein 5).
Novel drivers
Many of the driver mutations identified in this study
have not previously been linked to glioblastoma and/or
ovarian carcinoma. As far as we could see, around 30 of
the GBM drivers identified in this work were neither
known members of cancer pathways nor mutated in can-
cers of the central nervous system other than those from
the TCGA dataset. More specifically, a number of the
identified protein kinases had not previously been known
for their involvement in glioblastoma multiforme, although
the literature does contain some indirect evidence suggest-
ing that they may be tumor suppressors or oncogenes.
On the other hand, some of the identified drivers were
previously known to be involved in cancer; these are
discussed here.
The possibility that the protein kinase ATR may play
a role in cancer was first revealed quite recently, byToledo et al. [44]; these authors found that when acti-
vated by replication, this protein locally protects repli-
cation forks and globally suppresses origin firing.
Cerami et al. [28] identified a functional module of 4
genes (DCTN2, TUBGCP2, TUBGCP6, and FGFR1OP)
that encode components of the centrosome and micro-
tubule organizing center. By testing the data analyzed
by these workers using our 1point-vs-MGS procedure,
we found that another protein kinase ATM should be
included in this module because it was a likely driver
in two GBM and in two OV genomes. The kinase
CSNK1E had been previously associated only with
non-brain cancers [45,46], while HIPK2, LYN, and
EPHB4 have been suggested as targets for anti-tumor
therapies [47-49]. PIK3C2B was considered to be a
possible cause of resistance to erlotinib during the
later stages of glioblastoma, i.e. it may become a driver
in tumors that have evolved beyond a certain point
[50].
In general, the top ranking driver point mutations and
copy number changes were significantly more likely to
affect genes encoding protein kinases (PK) and transcrip-
tion factors (TF) than other types of genes. These two cat-
egories exhibited both gene set enrichment, i.e. they were
Table 1 Enrichment of genes encoding protein kinases, transcription factors, and genes linked to these categories in
the global network



















GBM Point mutations 277 40863 Protein kinase activity 277 49534 50 1.10e-63 3680 0.00e + 00
Point mutations 277 40863 Regulation of transcription,
DNA dependent
453 84621 19 1.05e-05 2340 1.14e-40
Copy number 455 49817 Protein kinase activity 277 49534 32 2.79e-18 3379 0.00e + 00
Copy number 455 49817 Regulation of transcription,
DNA dependent
453 84621 40 2.99e-16 2817 1.87e-44
OV Point mutations 1611 168022 Protein kinase activity 277 49534 103 1.52e-50 10941 0.00e + 00
Point mutations 1611 168022 Regulation of transcription,
DNA-dependent
453 84621 93 8.99e-19 9766 0.00e + 00
Copy number 168 24513 Protein kinase activity 277 49534 12 1.71e-07 1247 0.00e + 00
Copy number 168 24513 Regulation of transcription,
DNA-dependent
453 84621 7 0.29 1289 1.15e-11
FDR (GSEA): significance for fractions of PK and TF as shared genes.
FDR (NEA): significance for fractions of genes connected to PK and TF in the network.
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network enrichment, i.e. there was an over-representation
of network edges connecting other drivers to PK and TF
genes such as RUNX1, SIK1, ETS2, VSX1, FOXA2, SOX1,
BMP2, TP53BP1 in the GBM set and TGFBR2, ACVR1,
ACVR2A, WNT6, WNT16, STAT4, PRKRA, PDGFRA,
PAX4, GLI3 in the OV set (Table 1).
Comparison with existing methods and gene sets
It should be noted that each of the three major classes of
methods possessed own features, which did not allow a
symmetric, uniform comparison. Namely, the methods that
used sequence and frequency were both less dependent on
existing knowledge, although not entirely free of it. For com-
parison, the network methods could explicitly employ litera-
ture data in the form of known pathways, edges of the
global network etc. Next, both the sequence and network
based methods were applicable to events of any frequency,
including unique ones. And lastly, both the frequency and
network based methods could use plane genes symbols,
whereas the sequence analysis required specifying nucleotide
changes exactly. These circumstances warranted applying
specific approaches to the comparisons presented below.
Sequence analysis methods and mutation frequency
approaches
Sequence-based methods tend to be specialized for the
analysis of specific mutation types such as copy number
changes, gene fusions, or short insertions/deletions/sub-
stitutions. They evaluate concrete alterations of the nu-
cleotide sequence in each gene and assess their potential
impact on the protein’s function. If the predicted impact
is strong, the mutation is deemed damaging.In order to compare NEA with sequence-based methods,
we uniformly submitted the point mutations from the
GBM and OV sets to three web services that can estimate
the impact of point mutations on peptide chain functional-
ity: Mutation Assessor [51], PolyPhen-2 [52,53], and SIFT
[54]. Of course, the classifications obtained using these ser-
vices are not identical to those used when defining driver
mutations in cancer biology, but they are what cancer sci-
entists look for when using these resources. The methods’
efficiency was probably limited by a lack of information on
homologous sequences and protein structures in their da-
tabases, although the extent to which they rely on such in-
formation varies.
The overall positive rate of the sequence-based methods
was very high. For example, around 40% of 4896 muta-
tions in the OV genomes were predicted to be damaging
by at least one of the three sequence-based tools (while as
few as 3% were identified as potential drivers by 1point-
vs-MGS NEA at FDR <0.1). On the other hand, one would
expect to see functionally significant peptide chain
alterations in most frequently mutated genes. We did note
that 70-80% of EGFR (in OV) and TP53 (in both OV and
GBM) mutations were predicted to be either high impact
or damaging. However, this was not the case for most of
the other genes that were mutated in more than five (and
up to 70) genomes each (NF1, IDH1 etc.). Between 35 and
40% of mutations in these genes were classified as having
“damaging” or “high” impact, which is no greater than the
rate for genes in which mutations occurred only once
(Additional file 4: Figure S7, discussed in the next section).
Furthermore, these high positive rates did not decrease in
the OV set, where mutations in ~13000 genes were
analyzed. For example, the group of 3899 genes mutated
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to 40%. This was a counterintuitive result, especially when
compared to the GBM set with its ~500 mutated genes
pre-selected by known implication in cancer. Considering
the sequence analysis results in the gold standard sets of
frequently mutated and validated GBM drivers from
Parsons et al. [5] and Vogelstein et al. [19], we also could
not see much difference from the bulk of the genes. Fi-
nally, the three methods were in equally poor agreement
with each other as with our method (Additional file 4:
Figure S4). It could be noted that a smaller fraction of
mutations were identified by all the four (including our
NEA) methods (35 and 791 in GBM and OV, respectively),
but these were mostly the well known cancer drivers.
The set of drivers predicted by 1-point-vs-MGS NEA
at FDR < 0.1 only exhibited a formal overlap with the re-
sults obtained using two tools, GeneSift and PolyPhen-2
(and only in the GBM and not in the OV dataset). The
1-point-vs-MGS NEA agreed quite well with respect to
frequency: frequent mutators were classified as drivers
much more often than single-case mutators (5 - 32%
compared to 3 - 5% based on the pooled GBM and OV
results). As explained above, the sequence based tools
did not show such agreement.
There were still remarkable exceptions. Many known
drivers such as TP53, PTEN, RB1 etc. did not receive
any significant 1point-vs-MGS scores in genomes with
few point mutations. On the other hand, these genes
were detected by 1-vs-CPW analysis. As another ex-
ample, NEA missed nearly all of the mutations in IDH1,
an enzyme with acknowledged involvement in GBM
[55], because of its unique global role in DNA methyla-
tion, which was not reflected in our network.
Further, despite the poor correspondence between the se-
quence tools and NEA, the results obtained with the latter
were in good agreement with the basic variant classification
data available from the TCGA maf files. The strengths of
the differences between silent mutations and those classi-
fied as either “missense” or “nonsense” increased with the
confidence of the NEA analysis: mutations with 1-point-
vs-MGS NEA z-scores of > 10 exhibited the most signifi-
cant overlap with the “missense OR nonsense” category
(p-values of p < 0.01 according to Fisher’s exact test for
GBM and p < 0.00001 for OV; Additional file 4: Figure S5).
We conclude that sequence-based methods are likely
to yield very high positive rates, which seems especially
counter-intuitive when whole-exome mutations sets
are analyzed (such as the OV set). Moreover, they are
only consistently efficient for a few well-characterized
genes such as EGFR and TP53. However, NEA also has
some significant limitations, including its inapplicabil-
ity to rare mutations in small mutation sets and genes
with very special roles (e.g. those that extend beyond
well-characterized signaling pathways).Gold standard sets
We also compared the results of our NEA tests to selected
gold standard driver lists, namely:
1) 42 GBM CNA-genes presented by Parsons et al. ([5],
see Additional file 4: Table S7 to that article), and
two lists created by Vogelstein et al. [19];
2) 43 cancer predisposition genes ([19], Additional
file 4: Table S4);
3) 138 mut-driver genes ([19], Additional file 4: Tables
S2A and S2B).
List (1) was compiled based on an integrated analysis
of sequence changes, amplifications, and homozygous
deletions, and had three different p-value levels for each
gene (Passenger Probability Low, Passenger Probability
Mid, and Passenger Probability High). We could there-
fore calculate the correlations between each of these
three categories and the three NEA p-values obtained
using the 1-vs-CPW, 1-point-vs-MGS, and 1CNA-vs-
MGS procedures (Additional file 4: Figure S6A). Despite
the very small gene sets used (11 to 33 genes were avail-
able for each comparison), the overlaps proved to be
stable and positive.
The list (2) was compiled from the Cancer Gene Cen-
sus and did not contain quantitative scores, so we could
only calculate the enrichment of NEA-prioritized genes
in this list (Additional file 4: Figure S6B). Again, there
was significant and stable concordance despite the small
number of overlapping genes in the two sets. The signifi-
cance of enrichment increased with the stringency of the
combined NEA p-value cut-off (in all of the 1-vs-CPW,
1point-vs-MGS, and 1CNA-vs-MGS analyses).
Finally, the strongest concordance was observed be-
tween the NEA p-values and the mut-driver list (3). The
latter was compiled by Vogelstein and co-authors [19]
according to their “20/20 rule”, which states that a gene
can be classified as an oncogene if at least 20% of its
recorded mutations are missense mutations that occur
at recurrent positions, and as a tumor suppressor gene if
at least 20% of its recorded mutations are inactivating.
Of the 134 genes that were included in both sets, 101
had 1-vs-CPW p-values of <0.001 (FDR < 0.05). Of the
133 genes available for 1CNA-vs-MGS analysis, p-values
of <0.001 were observed for 50 and 48 genes in the
GBM and OV sets, respectively (the results were com-
bined across MGSs). Finally, of the 52 and 39 genes
from the mut-list that had somatic point mutations in
the GBM and OV sets, 22 and 6, respectively, had
1point-vs-MGS p-values of <0.001 (also combined across
MGSs). Enrichment by Fisher’s exact test in these
analyses was significant at all cutoffs (data not shown).
When the positive predictive rates of the network ana-
lysis were plotted against relative mutation frequencies
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et al. [5] and Vogelstein et al. [19] (which were both
based on the glioblastoma multiforme analyses) demon-
strated somewhat better results than the sets of all the
mutations of the TCGA GBM and OV sets (Additional
file 4: Figure S7). However, the difference was not found
significant: frequent mutators of both the gold standard
sets and in the bulk of TCGA genes demonstrated
higher rates of positive NEA predictions.
We conclude that the validity of the NEA results was
confirmed by their significant overlap with these three
published gene collections. We also note that although
the mut-drivers were discovered by analyzing point mu-
tations, many of the genes in the GBM and OV sets ex-
hibited driver copy number alterations as well.
Validation by co-occurrence of mutations
Given the assumption that driver perturbations in multiple
key sub-pathways are required for cancer development, one
might expect genes from different network domains to ex-
hibit co-occurring mutations in cancer MGS. The presence
of such non-random patterns would provide alternative evi-
dence that a given gene is a driver. Conversely, passenger
point mutations would not be expected to behave in this
way. It should be noted that CNA pairs were not analyzed
in this way because of their positional interdependence. We
calculated the associations between pairs of somatic point
mutations and between somatic point mutations and
CNAs. Significant ones were found both for genes with fre-
quent mutations (TP53, PTEN, DST, RB1, IDH1) and for
genes in which these events were rare. Many of the latter
category were affected by CNA (as shown in Table 2).
To verify the consistency of these patterns using NEA,
we compared the summed 1point-vs-MGS NEA scores
across all samples in which a given gene had point muta-
tions to the number of co-occurrences with any other
mutation. The list of predicted drivers with high sums
overlapped significantly with the list of genes with co-
occurring mutations (Additional file 4: Figure S8; one-
sided binomial test p-values of 0.00027 and 0.000008
were achieved for GBM and OV, respectively). Import-
antly, pairs of genes with correlated mutation patterns
were usually not directly connected by network edges
(we found only 35 such pairs in total). Nonetheless, ourTable 2 Representative 2x2 table of mutation
co-occurrence across GBM genomic samples (Fisher’s exact
test p0 = 2.6
−07)
Point mutation in FN1
Yes No
Point mutation in MSH6 Yes 4 0
No 1 143method was able to characterize these genes as drivers
by utilizing higher-order interactions involving multiple
genes as shown in Figure 5 and discussed at length above.
This stands in contrast to the results obtained by Ciriello
at al. [29], who based their mutual exclusivity modules on
known links in a protein interaction network.
Thus, the co-occurrence analysis in pairs of driver mu-
tations confirmed the overall validity of NEA. When ap-
plied to mutations from the same sets, the results
obtained were practically independent of the network
context. As described above, we utilized the association
analysis as an auxiliary part of our method.
Comparison to MEMo algorithm
Most of the methods of network analysis could only dis-
cover multi-genic entities such as network modules, pu-
tative pathways, motifs, gene signatures etc. and thus
were not directly comparable to our method. However,
we could still use the results published by Ciriello at al.
[29] by considering individual genes from their modules.
Their MEMo algorithm was applied to the same data
with a different approach: by pooling genomic samples
they discovered groups of frequent mutations that were
negatively correlated with each other and fully con-
nected in the network of protein-protein interactions.
Due to these strict requirements, the list of significant
modules was quite short and most of the members (in
total, 19 genes in GBM and OV in either of the two net-
work versions by requiring FDR < 0.1) were assigned to
multiple modules. We found that our analysis success-
fully assigned very low combined NEA p-values (below
10−10) to all the 13 GBM genes and to 5 out of 7 OV
genes identified by MEMo. It should be noted, however,
that there were crucial differences between MEMo and
our approach. First of all, we were more flexible by look-
ing at individual mutations and by defining network en-
richment in a much looser manner. In addition, the
detection of negative correlations needed for MEMo is
generally much more challenging than that of positive
ones (as described in the previous section) because most
of the mutations have low marginal frequencies.
Discussion and conclusion
The mutated gene sets for glioblastoma and ovarian tu-
mors contained both driver and passenger mutations. Syn-
ergies between drivers in individual tumors were
elucidated via their functional connectivity in the cancer
interactome. Using our network-based method, we dem-
onstrated that more than half of the point mutations in
the GBM set and around 1/6th of those in the OV set had
some functional involvement in the corresponding can-
cers. While these cancers may involve different mutation
mechanisms, the poorer results in the latter set are prob-
ably due to the different sequencing approaches used in
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first set compiled for TCGA and features mutations from
a limited set of only around 600 pre-selected genes with
either known or suspected involvement in glioblastoma.
Conversely, the OV set contains data from full-exome se-
quencing. The latter approach yielded a much greater pro-
portion of passenger mutations, and this result should be
primarily attributed to the less focused genomic approach
rather than to a lower precision of the analysis per se. Ap-
plying our method to the copy number alterations in each
of the two collections revealed between 300 and 600
driver CNA cases, depending on the applied confidence
threshold.
We reiterate that in the 1-vs-CPW tests any gene
could be analyzed against third party pathway sets re-
gardless of other genes in the somatic genome. On the
contrary, the 1point-vs-MGS and 1CNA-vs-MGS proce-
dures consider other alterations in the same genomes, i.
e. they are genuinely local tests. Importantly, the local
tests detected certain driver genes in novel genomic con-
texts (Figure 7). The applicability of these analyses will
increase with the declining costs of full-exome and full-
genome sequencing, growing confidence in the global
network, and the progressive incorporation of data on
methylation and germline variants etc.
A number of genes exhibited point mutations in some
genomes, CNAs in others, and both in a third group.
However, the 1-vs-CPW, 1point-vs-MGS, and 1CNA-vs-
MGS scores of individual genes correlated with one-
another quite well (Additional file 4: Figure S2). We take
this to mean that in appropriate genomic contexts, a
given gene may become a driver due to either a copy-
number change or a point mutation.
Many existing methods for validating CNA drivers
match observed copy numbers to expression of the af-
fected gene. However, neighboring genes might haveFigure 7 The driver role of the sodium channel voltage-gated type III
different, non-overlapping sets of point mutations in two OV genomesynchronized expression changes regardless of their
driver activity. We did observe an overall correlation
between CNA and expression level (median Spearman
rank r = 0.2…0.4; see Additional file 4: Figure S3B, top
pane). However, this was not a reliable indicator of
driver status. Indeed, the correlations for known
drivers such as those reported by Parsons et al. [5] and
Vogelstein et al. [19] were not stronger than those for
the whole set of studied genes (Additional file 4: Figure
S3A). One common exception was EGFR, a driver with
extraordinarily high amplification levels (up to 100-
fold). In our network analysis, the likelihood of being
identified as a driver was also not associated with the
CNA-expression correlation (Additional file 4: Figure
S3B, C, D). Relying on this weak overall correlation
would have led to prohibitively high false negative
rates. Akavia et al. [20] pointed out that many drivers
should be less correlated with their copy numbers than
passengers as a result of “selection pressure”, by which
they presumably meant negative feedback in regulatory
networks.
We also observed poor agreement between the tested
sequence-based methods and NEA. On the other hand,
there was significant correspondence between the NEA
results on the one hand and both frequency-based esti-
mates and lists of known cancer genes on the other
hand.
The sensitivity of the 1point-vs-MGS procedure was
dependent on the size of the analyzed MGS. No MGS with
fewer than four genes produced any positive results (such
samples were rare though). On the other hand, we observed
a tendency for known, frequent drivers with strong muta-
tion effects to occur more frequently in genomes with small
MGS. The effects of these genes (TP53, RB1, PTEN) were
probably strong enough to generate malignant phenotypes
on their own. Despite their limited amenability to 1point-beta subunit SCN3B was likely implemented via network links to
s. Red nodes indicate point mutations in the same tumor genome.
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bined procedure because they had many connections in
cancer pathways. As a result, their driver roles were discov-
ered in the 1-vs-CPW test. We also identified significant
correlations between all the three types of NEA (Additional
file 4: Figure S2).
Based on the demonstrated strengths and limitations
of each approach, we argue that there is a large unoccu-
pied niche for network enrichment analysis. In essence,
the method requires information on the context of the
somatic genome of interest, relevant pathways, and the
connections between genes in the global network. It
could be indispensable while integrating molecular
mechanisms of cancer, in cases where large sample
collections are unavailable, and when making clinical
decisions concerning the treatment of specific individ-
uals where being able to answer the question “What
has gone wrong in this tissue?” would enable the selec-




This section describes the calculation of NEA Z scores
as implemented in the script NEA.pl which we make
publicly available at http://research.scilifelab.se/andrej_
alexeyenko/downloads.html. The calculation is used in
1point-vs-MGS, 1CNA-vs-MGS, and 1-vs-CPW tests
described in the Results.
For each potential driver gene i, the confidence of its
functional relatedness to a group G was estimated using




where niG was the number of edges between i and any
gene j : j ∈G; i ≠ j found in the given network. In the
procedures presented in Figure 1, 1point-vs-MGS as-
sumed i ∈G, whereas 1CNA-vs-MGS and 1-vs-MGS
allowed any scenario. However, in the analyses i was
treated as an external node in all three cases.
For procedure 1 from Figure 1, we tested the general




niG; hence z ¼ n⋅G−n^⋅G
σ ⋅G
In biological networks, the distribution of node degree
(number of edges per node) follows a power law, i.e. it is
very uneven: there are many nodes with either one or
few links, while a few nodes have many (tens, hundreds,
or even thousands) links. Thus the statistics would be
strongly affected by the gene composition of particular
sets. In order to obtain values for the expected (mean)number n^iG and standard deviation σiG, we randomized
the network according to Maslov and Sneppen [56]. By
systematically re-wiring network nodes, i.e. swapping
edges between two nodes at a time, one can preserve node
degrees and the total number of edges in the network.
Hence, the biological content of the network is assumed
to be removed while preserving its topological properties.
The expected mean n^iG and standard deviation σiG were
determined after a sufficient number (25) of network
randomizations. Then n^iG was calculated for the ran-
domized network in the same way as niG in the actual
network. Alternatively, we used a network metric that
counted indirect links, i.e. cases when nodes i and j
shared a neighbour node in the network. In this case,
niG and n^iG summarized the shared neighbors in all
possible i-j pairs (j ∈ G).
For the analysis, we considered only MGSs with at
least three genes in each set, i.e. those amenable to NEA
(which was 67.6% and 94.1% of all MGSs, respectively).
Altered gene sets
We defined sets of individual-specific somatic point
mutations (MGS) as all genes listed in TCGA maf tables
for GBM and OV cancers, irrespective of their “Variant_
Classification” label. Multiple mutations in the same
gene were collapsed into one case per sample.
Copy number alterations were accepted as significant
if the log2(copy number) value for the corresponding
gene coding region was below 0.35.
Functional gene sets
We took all of the pathways included in the KEGG data-
base [57] (as of 21 Apr. 2010), and delineated the follow-
ing three categories:
1) SIG, 68 pathways with signaling functionality,
retrieved by using the KEGG04* mask, plus
the group KEGG03320 “PPAR signaling pathway”
2) OTH, pathways other than signaling and disease
ones, retrieved by using the KEGG00*, KEGG01*,
KEGG02*, KEGG03* masks.
3) CAN, 15 cancer-related pathways, retrieved by using
the KEGG052* mask, plus the following custom
pathways:Pancreatic cancer pathway [4],
Breast cancer pathway [1],
Colorectal cancer pathway [1],
Glioblastoma multiforme cancer pathway [5],
26 significantly frequent lung cancer drivers [3],
T cell homing on tumor pathway [58],
epithelial-mesenchymal transition (courtesy of
S. Souchelnytskyi), and
tumor-specific pH-shift (courtesy of A. de Milito);
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hallmarks of cancer [60]:
GO:0001525 “Angiogenesis”,
GO:0001666 “Response to hypoxia”,
GO:0002347 “Response to tumor cell”,








GO:0032570 “Response to progesterone stimulus”,
GO:0032640 “TNF production”,
GO:0043120 “TNF binding”,
GO:0070848 “Response to growth factor stimulus”.
Global networks for benchmarking and analysis
See Additional file 4: Table S1.
Network benchmarks
The performance of different network versions in func-
tional analysis has never previously been evaluated system-
atically to our knowledge. It is thus not clear which
network should be used to test mutations. It is well recog-
nized that data integration networks, despite their vast
scope, have poor agreement with each other when judged
by straightforward overlap. It is hard to say why this is on
the global scale. However, it is fair to assume that both
false positive and false negative rates are high in both re-
source types, i.e. many false edges will be present and
many existing edges will be missed.
There are different ways of testing networks in terms of
completeness, confidence, and information content. The
most straightforward approach would be to count edges
shared by two or more networks. However, pairs of net-
works generated by different computational methods
would be hard to align and compare because of their dif-
ferent, often nonlinear edge weight relations and unequal
densities. Benchmarking based on a percentage of “true”
edges would require a gold standard network that would
be either incomplete (e.g. the pathways of the KEGG data-
base [57]) or abound in false positives (e.g. any network
generated by computational data integration). As a way of
accounting for the complex topologies generated by so-
phisticated analyses such as that implemented in the In-
genuity Pathway Analysis [Ingenuity® Systems, http://
www.ingenuity.com], Lena et al. [61] developed a scoring
system for comparing pathways. However even this
method is limited to well-trusted network domains.
With the aim of avoiding both excessively simplistic
and overly complex topological issues, we benchmarkednetworks using a method similar to that used for practical
driver discovery, i.e. by their ability to recapitulate the
known memberships of genes in functional groups (as illus-
trated in pane D of Figure 1). This network-based approach
was both biologically transparent and amenable to signifi-
cance estimation. Benchmarks that involved thousands of
individual membership cases were visualized as ROC
curves. Plotting the ROC curves required 1) positive (gold
standard) test sets of functional groups, 2) negative sets,
and 3) a variable parameter. These components are
described in the following paragraph.
In the connectivity tests, the number of correctly identi-
fied FGS members at a given z-score threshold estimated
the true positive rate. As positive test sets, we used the
KEGG pathways [57]. The results obtained by using alter-
native pathway databases were overall similar to those
obtained using the KEGG data, probably because these dif-
ferent resources utilized the same published experimental
evidence. We preferred KEGG because it enabled simple
and transparent classification of pathways into convenient
categories : 1) signaling (SIG), 2) other basic (OTH), and a
cancer-related (CAN) collection of pathways together with
a number of biological processes based on Gene Ontology
terms, and a few cancer pathways collected from the litera-
ture (described in the section on "Functional gene sets"
above).
To estimate the false positive rates, we simulated nega-
tive test sets by replacing each actual gene member with
a randomly picked gene with a matching node degree
(network connectivity) value. The scales of the false
positive and true positive axes were equal because each
test on an actual FGS member was matched with one
test on an allegedly false member. Some of the latter
would have been previously unknown true members or
“remote relatives” of the used pathways. These false
positive estimates were thus probably too conservative,
but still suitable for benchmarking.
NEA z-scores were employed as the variable param-
eter for ROC curve generation. For a single gene i that
belonged to a group G, the individual NEA z-score
conveyed enrichment in network connectivity between
i and the rest of the group G (Figure 1B,C,D). Each
NEA test attempted to reject a null hypothesis stating
that “there is no relationship between gene i and G”.
Counts of true positives versus false positives at de-
creasing z-score thresholds were thus used as Y and X
coordinates for ROC curve construction. This test
framework would be relatively robust to false positives
and false negative edges in the global network because
each test involved multiple edges. Edge weights were
not utilized, i.e. each network was presented as a fixed-
size graph defined at a certain edge confidence cutoff.
This was important when merging networks generated
by different methods. Another feature of the framework
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of lowest formal significance (NEA z = 1.97, i.e. the two-
tailed p = 0.01). For this reason, the area under ROC could
not be used to compare curves. Instead, we compared
sensitivity/specificity ratios at points where the false
discovery rate (FDR) of NEA was 0.1. In addition to this
criterion, we visually judged the ROC curves, requiring
both convexity and sensitivity (based on the total number
of recapitulated true members in all gene tests).
Using this framework, we evaluated a range of net-
works (detailed descriptions of the tested networks are
given in the Additional file 4: Table S1). The most im-
portant results are presented in Figure 2 and Additional
file 4: Figure S1. The first category included networks
from large scale data integration (LSDI): versions of
FunCoup (v. 1 and 2) and the last release (v.9) of the
STRING database. We compiled and tested versions of
these networks of different sizes and edge confidence
values. Secondly, it was possible that specific co-
expression in GBM and OV could be beneficial for can-
cer data analysis. For this reason, we evaluated so called
relevance networks in which cancer-specific relationships
(that were not considered in LSDI) were represented by
correlation coefficients between gene expression profiles
in GBM and OV. Finally, yet another way to obtain more
specific gene networks was reverse engineering of regula-
tory (otherwise called causal) links from high-throughput
cancer data. Two such networks were generated by us
from the GBM and OV data (wir1 and wir.OV.0.5, see
Additional file 4: Supplemental Methods), and one network
for the ovarian cancer OV_TRANSFAC was obtained from
the literature [62].
The benchmark demonstrated clear differences be-
tween the networks (Additional file 4: Figure S1). The
first observation was that the LSDI networks were su-
perior to all other alternatives, i.e. networks based on
physical protein-protein interactions or co-expression
relevance, reverse-engineered networks, and their
unions. The levels of performance were relatively similar
between the full LSDI networks, despite dramatic differ-
ences in their numbers of edges (which ranged from 1.4
to 4.6 million) and nodes (which ranged from 15.9 to
19.4 thousand genes). This similarity could be explained
by the fact that the edges of lower confidence in both
STRING and FunCoup networks had low experimental
support. In other words, the network performance was
mostly determined by core fractions of high confidence
edges with extensive support from the literature, co-
expression analysis etc. Further, we noted that the full
STRING network clearly outperformed the FunCoup
networks (Additional file 4: Figure S1A,C). However, it
was known that the STRING network, unlike those gen-
erated by FunCoup, included information from all of the
KEGG pathways by default. To perform a more faircomparison, we merged each of the networks with the
full set of KEGG links and CORUM protein complex
members and then equalized their numbers of edges by
selecting the most highly ranked edges in each net-
work. This procedure made the networks perform even
more similarly (Additional file 4: Figure S1B). However
FunCoup had a better ratio of sensitivity/(1 - specificity)
(11…12 compared to around 9 for STRING). In this
regard, STRING performed notably worse than the
mammal-focused version of FunCoup FClim (in all
benchmarks other than that relating to the OTH cat-
egory). The final selection was made based on the most
important, cancer-related category CAN (Figure 2). We
hypothesize that the CAN analysis was to the particular
disadvantage of STRING because it incorporates data
from homologous genes in prokaryotic organisms,
whereas FunCoup utilized only eukaryotic evidence
and strictly defined orthologs. FClim had the highest
fraction of evidence from human and other mamma-
lian (mouse and rat) data sources. Finally, we merged the
higher confidence network version FClim_HC2 with cu-
rated functional links from CORUM (protein complex
membership, [63]), Phosphosite (kinase-substrate pairs,
[64]), KEGG (pathways and protein complexes, [57]),
MSigDB (transcription factor-regulated gene pairs,
[58]), and our reverse-engineered network wir1. The
resulting network merged6_and_wir1_HC2 had the best
performance, i.e. the highest sensitivity/specificity ratio
and at least marginally higher convexity and total sensi-
tivity than any other network.
Coherence of genome-specific sets of point mutations
We evaluated the functional coherence of point mutations,
i.e. MGS members within each somatic cancer genome. By
considering direct links, significant coherence was detected
in 24 out of 98 (GBM) and in 6 out of 80 (OV) MGS (the
analysis was limited to samples with both point mutation
and copy number data, which was important in the follow-
ing steps). Furthermore, we quantified this coherence via
indirect links by quantifying shared neighbors between two
genes of interest. This analysis greatly increased the number
of MGS exhibiting significant coherence, to 46 out of 98
and 63 out of 80 in GBM and OV, respectively.
Normalization of 1-vs-CPW analysis
The network analysis based on known cancer pathways
(1-vs-CPW, Figure 1D) included tests against all of the
FGS listed in the section on “Functional gene sets” under
the CAN category. Due to the overlap of member
genes, these tests were highly correlated, and their
summative estimates required adjustment. One of these
FGS, KEGG05200, was a super-pathway which com-
bined genes from 14 specific KEGG cancer pathways
(254 out of 375 genes, plus 11 genes that were unique
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using KEGG05200 alone and 2) using summed NEA z-
scores from all cancer FGS. The results obtained in
both cases were significantly consistent, yielding p-
values in the formally acceptable range (p < 0.01). The
approach using KEGG05200 alone had the advantage of
providing directly interpretable p-values and FDR data.
However, for the sake of higher sensitivity, it was desir-
able to use all possible FGSs. For example, at a confi-
dence cut-off that corresponded to maximal concordance
of the two alternatives, 20 actual members of KEGG05200
were not detected when using this pathway alone but were
successfully detected based on the summed scores for all
cancer FGSs. To regularize the summed NEA z-scores
from multiple FGSs, they were divided by a factor of
10.16, which was the linear fit coefficient of KEGG05200
against the sum of other cancer FGSs. Next, we estab-
lished that an NEA FDR of 0.1 corresponded to an NEA
z-score of 30.17/10.16 = 2.97. Hence in the following ana-
lysis, we accepted NEA z/10.16 = 2.97 as the lowest signifi-
cance cut-off.
Combining p-values from multiple tests
Fisher’s combined p-value [65] assumes the calculation





which can then be routinely converted to a p-value that
summarizes multiple tests.
Using this formula, we calculated different combinations
of p-values. Fisher’s formula assumes that the individual
tests to be combined are independent, which cannot be
entirely guaranteed in our analysis. As we were not aware
of any unbiased procedures to adjust for multiple testing
in this context, the combined p-values were used only for
ranking and prioritization.
CNA genes
The following procedure was applied for each gene with
multiple CNA cases (requiring absolute values of log2
(copy number) > 0.35 in at least 3 genomes within either
the GBM or the OV dataset):
1) First, we selected only CNA genes that significantly
co-occurred with any point mutations. Cases of co-
occurrence of the CNA gene with a point mutation
gene (requiring pFisher’s exact test < 0.01) were
combined as follows:
Χ2co−occurrence with point mutations ¼ −2 
XNco−occurring point mutations
i¼1
log pFisher0s exact testð Þ2) For each copy number-altered gene, we had a NEA
z-score and a corresponding p-value from the
1CNA-vs-MGS analysis from each of Nown_MGS









3) NEA z-scores from 1-vs-CPW analyses for individual
cancer pathways were positively correlated with each
other. Hence they were integrated as a linear sum,
then divided with the correction factor 10.16
(see “Normalization of 1-vs-CPW analysis”), and
converted to single values pNEA,cancer_pathways.
4. P-values from steps 1,2 and 3 were combined as:




pco−occurrence with po int mutations
þpNEA;own MGS þ pNEA;cancer pathwaysÞ
Genes with somatic point mutations
The mutation co-occurrence and 1CNA-vs-MGS ana-
lyses were not applicable here. Similarly to the above
described, we combined two relevant types of p-values:
Χ2po int mutation ¼ −2  ð logðpNEA;own MGS þ pNEA;cancer pathwaysÞ
Detection of functional consequences of mutations with
sequence-based tools
Several sequence-based methods for assessing the effects
of mutations on protein function have been developed. We
submitted input data for the GBM and OV sets (as de-
scribed below) and obtained output from the public web
servers Mutation Assessor [51], PolyPhen-2 [52,53] and
SIFT [54].
The Mutation Assessor web server (version 2.0 http://
mutationassessor.org/) used database versions Pfam 25
(November 2011), PDB (January 2012), RefSeq release 54,
UniProtKB/Swiss-Prot and UniProtKB/TrEMBL as of July
2012. The information is derived from aligned families and
sub-families of sequence homologs within and between
species using combinatorial entropy formalism to calculate
a functional impact score.
PolyPhen-2 web server (http://genetics.bwh.harvard.edu/
pph2/) used protein sequences from UniProtKB/UniRef
as of December 2011 and protein structures from PDB/
DSSP Snapshot as of 3 January 2012. The probabilistic
classifier of PolyPhen-2 used the HumDiv model to pre-
dict possible impacts of amino acid substitutions on the
protein structure and function based on such features as
sequence, phylogenetic, and structural information.
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edu.sg/www/SIFT_chr_coords_submit.html. SIFT does not
consider protein structures to assess consequences of
amino acid changes; instead, it uses a sequence conser-
vation approach to distinguish between intolerable and
tolerable amino acid substitutions and predict their impact
on protein function.
The sets of point mutations in GBM and OV were com-
piled from the TCGA maf files, whose data was extracted
in the following format: <chromosome>, <position>,
<reference allele>, <substituted allele>. The functional
effects of amino acid substitutions were predicted using
NCBI build 36 of the human genome. We applied the
score thresholds suggested by the authors of each method.
Mutation Assessor classified variants into four classes
(high impact, medium impact, low impact, and neutral).
In our comparison, high- and medium-impact predictions
were assigned a deleterious phenotype while other muta-
tions were considered neutral. PolyPhen-2 provided three
prediction classes (benign, possibly damaging, and prob-
ably damaging). In our comparison, ‘benign’ was assumed
to represent a neutral phenotype and the other two cat-
egories were assigned to deleterious phenotypes. SIFT
quantified tolerated and deleterious effects via a probabil-
ity that was normalized by amino acid class. Values below
0.05 were considered deleterious; otherwise the mutations
were deemed neutral. All the three tools could leave a
fraction of mutations without any prediction. In our com-
parisons, such mutations were included with the negative
test results, i.e. were considered neutral.
Availability of supporting data
The supporting data to this article are included as add-
itional files (probabilistic estimates of the driver analysis
and chromosomal maps of copy number analysis). The
software for the analysis as well as the global network of
functional couplings are publicly available at http://re-
search.scilifelab.se/andrej_alexeyenko/downloads.html.
Additional files
Additional file 1: [Drivers.xlsx] contains the results of probabilistic
analysis of both point and copy number mutations in the GBM and
OV genomes. The first two sheets contain systematic evaluation of all the
mutations, whereas the latter two sheets present single-genome examples.
Additional file 2: [GBM.CNA_and_M2CH.alongChromosomes.v7.pdf]
contains a graphical representation of copy number driver analysis
along the chromosomes in glioblastoma multiforme.
Additional file 3: [OV.CNA_and_M2CH.alongChromosomes.v7.pdf]
contains a graphical representation of copy number driver analysis
along the chromosomes in ovarian carcinoma.
Additional file 4: [Drivers_in_glioblastoma.Supplementary.July29.
docx] contains supplementary methods (reverse engineering of
network wir1), tables (the descriptions of benchmarked networks
and the re-analysis of results from Ciriello et al. [29]) as well as the
supplementary figures.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SKM analyzed and visualized the input data, performed calibration, and
prepared figures for the manuscript. DG processed, evaluated, and
performed statistical analysis of the input data. AA designed the method and
wrote software. All authors worked on the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The authors thank the Science for Life Laboratory, the National Genomics
Infrastructure, and PDC Center for High Performance Computing (all resided in
Sweden) for support and computational infrastructure. The support by BILS
(Bioinformatics Infrastructure for Life Sciences) is gratefully acknowledged, too.
Author details
1Master program in Bioinformatics at Department of Biochemistry and
Biophysics, Science for Life Laboratory, Stockholm University, Box 1031, 171
21 Solna, Sweden. 2Present address: Institute of Environmental Medicine,
Karolinska Institutet, Box 210, SE-171 77 Stockholm, Sweden. 3Department of
Biochemistry and Biophysics, Science for Life Laboratory, Stockholm
University, Box 1031, 171 21 Solna, Sweden. 4Present address: Max Planck
Institute for Human Cognitive and Brain Sciences, Stephanstraße 1a, 04103
Leipzig, Germany. 5Department of Microbiology, Tumour and Cell biology,
Bioinformatics Infrastructure for Life Sciences, Science for Life Laboratory,
Karolinska Institutet, 17177 Stockholm, Sweden.
Received: 7 May 2014 Accepted: 2 September 2014
Published: 19 September 2014
References
1. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary
RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD,
Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G,
Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE:
The consensus coding sequences of human breast and colorectal cancers.
Science 2006, 314(5797):268–274. Epub 2006 Sep 7.
2. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G,
Davies H, Teague J, Butler A, Stevens C, Edkins S, O’Meara S, Vastrik I,
Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B,
Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K,
Hinton J, Jenkinson A, Jones D, et al: Patterns of somatic mutation in
human cancer genomes. Nature 2007, 446:153–158.
3. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C,
Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC,
Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H,
Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc
K, et al: Somatic mutations affect key pathways in lung adenocarcinoma.
Nature 2008, 455(7216):1069–1075.
4. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P,
Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES,
Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR,
Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A,
Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, et al: Core
signaling pathways in human pancreatic cancers revealed by global
genomic analyses. Science 2008, 321(5897):1801–1806.
5. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter
H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T,
Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg
RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos
N, Parmigiani G, et al: An integrated genomic analysis of human
glioblastoma multiforme. Science 2008, 321(5897):1807–1812.
6. Huang S, Ernberg I, Kauffman S: Cancer attractors: a systems view of tumors
from a gene network dynamics and developmental perspective. Semin Cell
Dev Biol 2009, 20(7):869–876.
7. Krause DS, Van Etten RA: Tyrosine kinases as targets for cancer therapy.
N Engl J Med 2005, 353(2):172–187.
8. Nelander S, Wang W, Nilsson B, She Q-B, Pratilas C, Rosen N, Gennemark P, Sander
C:Models from experiments: combinatorial drug perturbations of cancer cells.
Mol Syst Biol 2008, 4(1):1.
Merid et al. BMC Bioinformatics 2014, 15:308 Page 20 of 21
http://www.biomedcentral.com/1471-2105/15/3089. Basanta D, Gatenby RA, Anderson AR: Exploiting evolution to treat drug
resistance: combination therapy and the double bind. Mol Pharm 2012,
9(4):914–921.
10. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, Yaffe MB:
Sequential application of anticancer drugs enhances cell death by rewiring
apoptotic signaling networks. Cell 2012, 149(4):780–794.
11. Kraggerud SM, Hoei-Hansen CE, Alagaratnam S, Skotheim RI, Abeler VM,
Rajpert-De Meyts E, Lothe RA: Molecular characteristics of malignant
ovarian germ cell tumors and comparison with testicular counterparts:
implications for pathogenesis. Endocr Rev 2013, 34(3):339–376.
doi:10.1210/er.2012-1045.
12. Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW,
Vogelstein B, Karchin R: Cancer-specific high-throughput annotation
of somatic mutations: computational prediction of driver missense
mutations. Cancer Res 2009, 69(16):6660–6667. Epub 2009 Aug 4.
13. Cancer Genome Atlas Research Network: Integrated genomic analyses of
ovarian carcinoma. Nature 2011, 474(7353):609–615.
14. Cerutti P, Hussain P, Pourzand C, Aguilar F: Mutagenesis of the H-ras
protooncogene and the p53 tumor suppressor gene. Cancer Res 1994,
54(7 Suppl):1934s–1938s.
15. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT,
Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer
C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C,
Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes
HE, Foekens JA, Reis-Filho JS, Van ‘t Veer L, Richardson AL, Børresen-Dale AL,
et al: Complex landscapes of somatic rearrangement in human breast
cancer genomes. Nature 2009, 462(7276):1005–1010.
16. Kaminker JS, Zhang Y, Watanabe C, Zhang Z: Canpredict: a computational
tool for predicting cancer-associated missense mutations. Nucleic Acids
Res 2007, 35:W595–W598.
17. Torkamani A, Schork NJ: Prediction of cancer driver mutations in
protein kinases. Cancer Res 2008, 68(6):1675–1682.
18. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S,
Sjöblom T, Park BH, Parsons R, Willis J, Dawson D, Willson JK, Nikolskaya
T, Nikolsky Y, Kopelovich L, Papadopoulos N, Pennacchio LA, Wang TL,
Markowitz SD, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE:
Integrated analysis of homozygous deletions, focal amplifications,
and sequence alterations in breast and colorectal cancers. Proc Natl
Acad Sci U S A 2008, 105:16224–16229.
19. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW:
Cancer genome landscapes. Science 2013, 339(6127):1546–1558.
20. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC,
Pochanard P, Mozes E, Garraway LA, Pe’er D: An integrated approach to
uncover drivers of cancer. Cell 2010, 143(6):1005–1017.
21. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco
I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H,
Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA,
Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M,
Golub TA, Lander ES, Mellinghoff IK, et al: Assessing the significance of
chromosomal aberrations in cancer: methodology and application to
glioma. Proc Natl Acad Sci U S A 2007, 104(50):20007–20012.
22. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C: Emerging
landscape of oncogenic signatures across human cancers. Nat Genet 2013,
45(10):1127–1133.
23. The International Cancer Genome Consortium: International network of
cancer genome projects. Nature 2010, 464:993–998.
24. Ideker T, Sharan R: Protein networks in disease. Genome Res 2008, 18:644–652.
25. Alexeyenko A, Sonnhammer EL: Global networks of functional coupling
in eukaryotes from comprehensive data integration. Genome Res 2009,
19(6):1107–1116.
26. The Cancer Genome Atlas Research Network: Comprehensive genomic
characterization defines human glioblastoma genes and core pathways.
Nature 2008, 455(7216):1061–1068.
27. Torkamani A, Schork NJ: Identification of rare cancer driver mutations by
network reconstruction. Genome Res 2009, 19(9):1570–1578.
28. Cerami E, Demir E, Schultz N, Taylor BS, Sander C: Automated network analysis
identifies core pathways in glioblastoma. PLoS One 2010, 5(2):e8918.
29. Ciriello G, Cerami E, Sander C, Schultz N: Mutual exclusivity analysis
identifies oncogenic network modules. Genome Res 2012, 22:398–406.
30. Gu Y, Wang H, Qin Y, Zhang Y, Zhao W, Qi L, Zhang Y, Wang C, Guo Z:
Network analysis of genomic alteration profiles reveals co-alteredfunctional modules and driver genes for glioblastoma. Mol BioSyst 2013,
9(3):467–477.
31. Babaei S, Hulsman M, Reinders M, de Ridder J: Detecting recurrent gene
mutation in interaction network context using multi-scale graph
diffusion. BMC Bioinformatics 2013, 14(1):29.
32. Alexeyenko A, Lee W, Pernemalm M, Guegan J, Dessen P, Lazar V, Lehtiö J,
Pawitan Y: Network enrichment analysis: extension of gene-set enrichment
analysis to gene networks. BMC Bioinformatics 2012, 13:226.
33. Alexeyenko A, Wassenberg DM, Lobenhofer EK, Yen J, Linney E,
Sonnhammer ELL, Meyer JN: Dynamic zebrafish interactome reveals
transcriptional mechanisms of dioxin toxicity. PLoS One 2010, 5(5):e10465.
34. McCormack T, Frings O, Alexeyenko A, Sonnhammer EL: Statistical
assessment of crosstalk enrichment between gene groups in biological
networks. PLoS One 2013, 8(1):e54945.
35. Reynolds CA, Hong MG, Eriksson UK, Blennow K, Wiklund F, Johansson B,
Malmberg B, Berg S, Alexeyenko A, Grönberg H, Gatz M, Pedersen NL,
Prince JA: Genetic association of sequence variants near AGER/NOTCH4
and dementia. J Alzheimers Dis 2011, 24(3):475–484.
36. Hong MG, Alexeyenko A, Lambert JC, Amouyel P, Prince JA: Genome-wide
pathway analysis implicates intracellular transmembrane protein
transport in Alzheimer disease. J Hum Genet 2010, 55(10):707–709.
37. Bennet AM, Reynolds CA, Eriksson UK, Hong MG, Blennow K, Gatz M, Alexeyenko
A, Pedersen NL, Prince JA: Genetic association of sequence variants near
AGER/NOTCH4 and dementia. J Alzheimers Dis 2011, 24(3):475–484.
38. Navlakha S, Kingsford C: The power of protein interaction networks for
associating genes with diseases. Bioinformatics 2010, 26(8):1057–1063.
39. Jansen R, Yu H, Greenbaum D, Kluger Y, Krogan NJ, Chung S, Emili A,
Snyder M, Greenblatt JF, Gerstein M: Bayesian networks approach for
predicting protein–protein interactions from genomic data. Science
2003, 302:449–453.
40. Troyanskaya OL, Dolinski K, Owen AB, Altman RB, Botstein DA: Bayesian network
for combining heterogeneous data sources for gene function prediction
(in Saccharomyces cerevisiae). Proc Natl Acad Sci 2003, 100:8348–8353.
41. Lee I, Date SV, Adai AT, Marcotte EM: A probabilistic functional network of
yeast genes. Science 2004, 306:1555–1558.
42. von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Foglierini M, Jouffre
N, Huynen MA, Bork P: STRING: Known and predicted protein–protein
associations, integrated and transferred across organisms. Nucleic Acids
Res 2005, 33:D433–D437.
43. Mammoto T, Jiang A, Jiang E, Panigrahy D, Kieran MW, Mammoto A: Role
of collagen matrix in tumor angiogenesis and glioblastoma multiforme
progression. Am J Pathol 2013, 183(4):1293–1305.
44. Toledo LI, Altmeyer M, Rask MB, Lukas C, Larsen DH, Povlsen LK, Bekker-Jensen S,
Mailand N, Bartek J, Lukas J: ATR prohibits replication catastrophe by preventing
global exhaustion of RPA. Cell 2013, 155(5):1088–1103.
45. Kim SY, Dunn IF, Firestein R, Gupta P, Wardwell L, Repich K, Schinzel AC,
Wittner B, Silver SJ, Root DE, Boehm JS, Ramaswamy S, Lander ES, Hahn WC:
CK-epsilon is required for breast cancers dependent on beta-catenin
activity. PLoS One 2010, 5(2):e8979.
46. Yang WS, Stockwell BR: Inhibition of casein kinase 1-epsilon induces
cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biol
2008, 9(6):R92.
47. Nardinocchi L, Puca R, Givol D, D’Orazi G: HIPK2-A therapeutical target to
be (re)activated for tumor suppression: Role in p53 activation and
HIF-1alpha inhibition. Cell Cycle 2010, 4:9(7).
48. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK,
Pollack JR: LYN is a mediator of epithelial-mesenchymal transition and a
target of dasatinib in breast cancer. Cancer Res 2010, 70(6):2296–2306.
49. Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS:
Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit
tumor growth. Am J Pathol 2010, 176(4):2029–2038.
50. Löw S, Vougioukas VI, Hielscher T, Schmidt U, Unterberg A, Halatsch ME:
Pathogenetic pathways leading to glioblastoma multiforme: association
between gene expressions and resistance to erlotinib. Anticancer Res
2008, 28(6A):3729–3732.
51. Reva B, Antipin Y, Sander C: Predicting the functional impact of protein
mutations: application to cancer genomics. Nucleic Acids Res 2011,
39(17):e118.
52. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
Kondrashov AS, Sunyaev SR: A method and server for predicting
damaging missense mutations. Nat Methods 2010, 7(4):248–249.
Merid et al. BMC Bioinformatics 2014, 15:308 Page 21 of 21
http://www.biomedcentral.com/1471-2105/15/30853. Adzhubei I, Jordan DM, Sunyaev SR: Predicting functional effect of human
missense mutations using PolyPhen-2. Curr Protoc Hum Genet 2013,
Chapter 7:Unit7.20.
54. Ng PC, Henikoff S: SIFT: Predicting amino acid changes that affect protein
function. Nucleic Acids Res 2003, 31(13):3812–3814.
55. Losman JA, Kaelin WG Jr: What a difference a hydroxyl makes:
mutant IDH,(R)-2-hydroxyglutarate, and cancer. Genes Dev 2013,
27(8):836–852.
56. Maslov S, Sneppen K: Specificity and stability in topology of protein
networks. Science 2002, 296(5569):910–913.
57. Kanehisa M, Goto S, Kawashima S, Nakaya A: The KEGG databases at
GenomeNet. Nucleic Acids Res 2002, 30:42–46.
58. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P,
Mesirov JP: Molecular signatures database (MSigDB) 3.0. Bioinformatics
2011, 27(12):1739–1740.
59. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP,
Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A,
Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene
ontology: tool for the unification of biology: The Gene Ontology
Consortium. Nat Genet 2000, 25(1):25–29.
60. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2011, 144(5):646–674.
61. Lena PD, Wu G, Martelli PL, Casadio R, Nardini C: MIMO: an efficient tool
for molecular interaction maps overlap. BMC Bioinformatics 2013, 14:159.
62. di Bernardo D, Thompson MJ, Gardner TS, Chobot SE, Eastwood EL,
Wojtovich AP, Elliott SJ, Schaus SE, Collins JJ: Chemogenomic profiling on
a genome-wide scale using reverse-engineered gene networks.
Nat Biotechnol 2005, 23:377–383.
63. Ruepp A, Waegele B, Lechner M, Brauner B, Dunger-Kaltenbach I, Fobo G,
Frishman G, Montrone C, Mewes HW: CORUM: the comprehensive
resource of mammalian protein complexes–2009. Nucleic Acids Res 2010,
38(Database issue):D497–D501.
64. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B,
Latham V, Sullivan M: PhosphoSitePlus: a comprehensive resource for
investigating the structure and function of experimentally determined
post-translational modifications in man and mouse. Nucleic Acids Res
2012, 40(Database issue):D261–D270.
65. Fisher RA: Statistical methods for research workers. Edinburgh: Oliver and
Boyd; 1925.
doi:10.1186/1471-2105-15-308
Cite this article as: Merid et al.: Distinguishing between driver and
passenger mutations in individual cancer genomes by network
enrichment analysis. BMC Bioinformatics 2014 15:308.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
